Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
8
Participants
Timeline
Start Date
November 21, 2022
Primary Completion Date
December 21, 2022
Study Completion Date
December 21, 2022
Conditions
Healthy Volunteers
Interventions
DRUG
[14C]-TVB-2640
50 mg of TVB-2640 oral administration
Trial Locations (1)
68502
Celerion Inc., Lincoln
All Listed Sponsors
lead
Sagimet Biosciences Inc.
INDUSTRY
NCT05657834 - Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects | Biotech Hunter | Biotech Hunter